Zura Bio set to showcase at the Jefferies Global Healthcare Gathering
Zura Bio Limited, a clinical-stage, multi-asset immunology company, has announced that it will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 3:10 PM ET in New York, NY.
The presentation, which will be live-streamed on the News & Events page in the Investors section of the Zura Bio website, will provide updates on the company's pipeline of novel dual-pathway antibodies for autoimmune and inflammatory diseases.
Two of Zura Bio's product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. These studies are for systemic sclerosis (TibuSURE) and hidradenitis suppurativa (TibuSHIELD).
The company's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies.
For those unable to attend the live presentation, a replay will be available on the website for at least 30 days following the event. To access the presentation, visitors can check Zura Bio’s investor relations page or the conference’s official website for the live webcast and replay links. Alternatively, inquiries can be directed to [email protected].
Megan K. Weinshank, the Head of Corporate Affairs at Zura Bio, will be a member of the senior leadership team presenting at the conference.
Zura Bio Limited (Nasdaq: ZURA) is based in New York, NY and can be found online at www.zurabio.com. This press release is from Business Wire.
At the Jefferies Global Healthcare Conference on June 4, 2025, Zura Bio will discuss updates on their pipeline of novel dual-pathway antibodies, including cloud-based access for the live-streamed presentation. In their research towards autoimmune and inflammatory diseases, science plays a crucial role in the development of therapies and treatments such as crebankitug (ZB-168) and torudokimab (ZB-880) for systemic sclerosis and hidradenitis suppurativa. Moreover, health-and-wellness initiatives are evident in Zura Bio's continuous efforts to improve patient lives through their innovative approaches.
